26 results
Thumbnail

D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children

Thumbnail

D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience

Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation

Thumbnail

D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report

Thumbnail

D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months

Thumbnail

D2.505 - Sustainable Allergy Management: a Task force report

Thumbnail

D2.507 - School dust Streptomyces and Mycobacterium exposure and respiratory health in European children: the SINPHONIE study

Thumbnail

D2.516 - Can social media track seasonal allergy burden? An evidence-weighted geo-location pipeline and validation against airborne pollen exposure in Augsburg, Germany

Thumbnail

D2.506 - Mold amounts decreased annual concentration, even some species faded away with allergic sensitization rate in Seoul for 28 years

Thumbnail

D2.508 - Climate Change, Allergic Diseases, and Mental Health in Outdoor Workers: A Transdisciplinary Perspective from CliMent COST Action

Thumbnail

D2.509 - Do macrophages modulate the response of injured bronchial epithelium after PM2.5 and microplastic exposure?

Thumbnail

D2.511 - Beyond PFAS: Atypical oral manifestation of eosinophilic esophagitis in a patient with birch allergy. Case Description